Latest News
Featured News
Edison Report – Redesigning immunity: The next frontier in immuno-oncology
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Scancell Financial Year End 2025 Results
Full steam ahead with iSCIB1+
Preliminary Results for the Year Ended 30 April 2025
Notice of Results
Director Dealing
Director Dealing
SCOPE’ing out iSCIB1+ in advanced melanoma
Scancell reports Strong Phase 2 Data on iSCIB1+ in Advanced Melanoma
Successful SCOPE outcome and iSCIB1+ selection
Active Immunotherapy for a Cancer-Free Future
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
Share Option Exercise
No results found.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.